T0	KEYPHRASE-NOTYPES 3 11	addition
T1	KEYPHRASE-NOTYPES 15 32	biofilm formation
T2	KEYPHRASE-NOTYPES 38 45	ability
T3	KEYPHRASE-NOTYPES 93 97	host
T4	KEYPHRASE-NOTYPES 121 145	echanismwhichmight favor
T5	KEYPHRASE-NOTYPES 157 177	persistent infection
T6	KEYPHRASE-NOTYPES 213 221	efficacy
T7	KEYPHRASE-NOTYPES 225 236	antibiotics
T8	KEYPHRASE-NOTYPES 283 302	extracellularmatrix
T9	KEYPHRASE-NOTYPES 312 323	antibiotics
T10	KEYPHRASE-NOTYPES 344 353	treatment
T11	KEYPHRASE-NOTYPES 357 359	LB
T12	KEYPHRASE-NOTYPES 364 380	first-line drugs
T13	KEYPHRASE-NOTYPES 384 416	several intracellular infections
T14	KEYPHRASE-NOTYPES 429 440	Doxycycline
T15	KEYPHRASE-NOTYPES 445 457	azithromycin
T16	KEYPHRASE-NOTYPES 484 493	treatment
T17	KEYPHRASE-NOTYPES 497 507	Mycoplasma
T18	KEYPHRASE-NOTYPES 509 518	Chlamydia
T19	KEYPHRASE-NOTYPES 524 534	Legionella
T20	KEYPHRASE-NOTYPES 542 553	ceftriaxone
T21	KEYPHRASE-NOTYPES 590 599	Neisseria
T22	KEYPHRASE-NOTYPES 605 616	amoxicillin
T23	KEYPHRASE-NOTYPES 634 653	Listeria infections
T24	KEYPHRASE-NOTYPES 680 698	biofilm production
T25	KEYPHRASE-NOTYPES 702 724	extracellular bacteria
T26	KEYPHRASE-NOTYPES 729 755	intracellular localization
T27	KEYPHRASE-NOTYPES 834 863	chronic bacterial persistence
T28	KEYPHRASE-NOTYPES 871 875	host
